CTOs on the Move

Abeo Management Corporation

www.abeo.com

 
abeo is a nationwide medical billing and software company focused on delivering revenue-enhancing services to private practices, hospitals and surgery centers. We bridge the gap between the constant change in healthcare and your changing needs as a result. We know the healthcare landscape; we know the complexities and regulations. Our professional management services, medical billing software and anesthesia advisory services are tailored to improve the operational and financial performance for the specialty of anesthesiology. We blend our employee expertise in anesthesia with process and technology to take efficiency to the next level. Operational best practices play a key role in our ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.abeo.com
  • 5001 LBJ Freeway Suite 320
    Dallas, TX USA 75244
  • Phone: 972.861.1270

Executives

Name Title Contact Details
Joe Ferro
Chief Technology and Innovation Officer Profile

Similar Companies

ACR Health

Opening Doors to Create Healthy Communities

Master Train Inc

Master Train Inc is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adia Information Management

Adia Information Management Corp. is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Angel's Harbor

Angels Harbor is a residential treatment facility located in Vincent, Ohio that offers inpatient residential treatment services to women struggling with substance use.

SetPoint Medical

SetPoint Medical is developing novel neuromodulation therapies to treat those who suffer from inflammatory diseases such as Crohn`s Disease and rheumatoid arthritis. The company is developing a proprietary and innovative neuromodulation therapy delivery platform consisting of a micro-regulator programmed via a unique prescription pad based interface. This novel therapy will provide patients and healthcare providers with a safe and efficacious alternative to drugs, while costing payors less than 50% of what today`s leading biologic therapies cost.